Exceeded Revenue and EPS Guidance
Second quarter revenues were $780.9 million, exceeding the high end of previous $769 million to $777 million guidance. Adjusted earnings per share were $3.73, a 9.1% increase year-over-year.
Strategic Acquisition and Growth
Completed acquisition of BIOTRONIK's Vascular Intervention business for EUR 704 million, expected to generate $204 million in revenue in the second half of 2025 and grow 6% or better annually starting 2026.
Strong Interventional Segment Performance
Interventional revenue increased 19.3% year-over-year, driven by growth in intra-aortic balloon pumps, catheters, OnControl, and complex catheters.
Tariff Impact Mitigation
Reduction in expected tariff impact for 2025 from $55 million to $29 million due to changes in tariff rates and mitigation strategies.